MN-DIGI-INTERNATIONAL
19.1.2023 10:01:43 CET | Business Wire | Press release
Digi International (NASDAQ: DGII, www.digi.com), a leading global provider of Internet of Things (IoT) solutions, connectivity products, and services, today launched two Digi ConnectCore® software service offerings – Digi ConnectCore® Cloud Services and Digi ConnectCore® Security Services. The offerings provide greater manageability and security for devices developed with Digi’s complete line of ConnectCore system-on-modules (SOMs).
Today’s OEMs – and their customers – need end-to-end hardware/software solutions to actively manage their device portfolios, gather data from devices in the field and deliver real-time updates and security patches as needed. Digi ConnectCore Cloud Services deliver the manageability they need to enable secure, over-the-air (OTA) software updates, access device data, and perform remote diagnostics, command and control. Digi ConnectCore Cloud Services also provide API access enabling custom applications and remote dashboards empowering OEMs to create innovative customer service plans.
Digi ConnectCore Security Services enable OEMs to maintain the security of products during their entire lifecycle and empower device makers to solve the ongoing challenge of keeping products secure after release. The services include the analysis and monitoring of a custom software bill of material (SBOM) and binary image running on Digi ConnectCore SOMs for security risks and vulnerabilities. To help remediate identified issues, the services provide a curated vulnerability report highlighting critical concerns, a security software layer including patches for common vulnerabilities, and consulting services.
Together, the two services provide a comprehensive software foundation that, in conjunction with Digi’s family of ConnectCore system-on-modules, enable OEMs to deliver highly secure, connected IoT products with increased product quality, improved technical support, and a stronger end-customer experience. Both Digi ConnectCore services support the entire family of Digi ConnectCore systems-on-modules.
Digi, an ST Authorized Partner, also announced the general availability of its Digi ConnectCore MP157 system-on-module (SOM), which leverages the STMicroelectronics STM32MP157C microprocessor and has a fully integrated dual-band Wi-Fi/BT interface. Now available in developer kits from Digi’s global channel partners, the tiny ConnectCore MP15 is ideal for handheld products with cameras and/or displays such as medical devices, environmental test equipment, industrial-grade human machine interfaces, or headless devices such as EV charging stations and renewable-energy controllers. By addressing the need to build intelligent, connected, and secure wireless products for healthcare, transportation, and industrial sectors, Digi ConnectCore MP1 SOMs offer unparalleled flexibility and scalability. The highly integrated solution includes a complete set of development tools, design support, software, and security building blocks to speed time to market.
“Digi ConnectCore Services continue our mission to reduce the complexity OEMs are facing with implementing full end-to-end industrial IoT solutions and simplify device security and management for our customers,” said Andreas Burghart, Senior Product Manager for Digi’s Embedded division. “The combination of innovative SOM hardware and software, cloud-based services, and comprehensive security improve our customers’ ability to deliver and manage secure, cost-effective solutions and extend our leadership in embedded systems.”
“Using the Digi ConnectCore MP1 SOM with integrated wireless capabilities reduces the design complexity significantly for OEMs, especially for companies that have designed products using the STM32 microcontroller portfolio,” said Jean-Philippe Moreno, Product Marketing Manager, STMicroelectronics. “For developers now moving into the higher performance microprocessor space, the Digi SOM solution reduces the risk significantly and helps to make this transition.”
For more information, visit Digi at the STMicroelectronics booth #447 at the IoT Solutions World Congress, Jan. 31–Feb. 2, 2023.
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005014/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom